Blood Disorders & Hematology Clinical Trials Update: Week 33, 2026

Published August 14, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML

This Phase 3 trial is studying whether adding umbilical cord blood infusions to chemotherapy can help older adults aged 60 to 80 with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach lowers the chance of the cancer returning and improves survival after patients reach remission. If successful, this could offer a new treatment path for older patients who often have fewer options due to the intensity of standard therapies.

Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma

This Phase 2 trial is testing a new combination of two drugs, teclistamab and pomalidomide, for adults whose multiple myeloma has returned or not responded to previous treatments. The study uses a different schedule for giving these drugs, which may improve how well the treatment works. Patients who have had one to three prior therapies are eligible, and the trial is taking place across several Nordic and Baltic countries.

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

This study is exploring whether adding a drug called acalabrutinib to standard chemotherapy (CHOP-R) can improve outcomes for people newly diagnosed with Richter's Syndrome, a rare and aggressive blood cancer. Conducted in specialized hospitals in the UK, the trial includes scans and biopsies to carefully monitor patient response. The hope is to find a better treatment option where currently few exist.

Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma

This Phase 2 trial is testing a new immunotherapy called Mosunetuzumab given under the skin for patients with low tumor burden follicular lymphoma who have not yet received treatment. This approach may be less invasive and provide an effective first treatment option. The trial is recruiting patients in Israel and aims to enroll 40 participants to better understand the benefits and side effects.

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

This Phase 2 trial is investigating a combination of azacitidine and enasidenib for adults with a specific genetic mutation (IDH2) in myelodysplastic syndrome, a blood condition that can lead to leukemia. By targeting the mutation, this treatment may better control the disease and offer an alternative to standard therapies. The study is recruiting high-risk patients in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.